Jaihwan Kim1, Danielle Braun2, Chinedu Ukaegbu3, Tara G Dhingra3, Fay Kastrinos4, Giovanni Parmigiani2, Sapna Syngal5, Matthew B Yurgelun6. 1. Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 2. Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York. 5. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 6. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: Matthew_Yurgelun@dfci.harvard.edu.
Abstract
BACKGROUND & AIMS: Lynch syndrome is the most common inherited cause of gastrointestinal cancer and increases risk for a variety of malignancies, including gastric cancer. We aimed to identify clinical factors associated with gastric cancer in carriers of germline variants causing Lynch syndrome. METHODS: We collected data from 52,758 consecutive individuals tested for genetic variants associated with Lynch syndrome from June 2006 through July 2013 at a commercial laboratory. We obtained clinical and demographic data, as well as information on personal and family histories of cancer (first- and second-degree relatives) from forms completed by ordering providers. We performed multivariate logistic regression to identify clinical factors associated with gastric cancer in carriers of mutations that cause Lynch syndrome (pathogenic mutations). RESULTS: After we excluded individuals with missing clinical data (n = 1664) or with multiple pathogenic mutations (n = 8), we analyzed data from 51,086 individuals. Of these, 3828 persons carried pathogenic mutations (1346 with mutations in MLH1, 1639 with mutations in MSH2, 670 with mutations in MSH6, 145 with mutations in PMS2, and 28 with mutations in EPCAM). Of the 3828 carriers of pathogenic mutations, 41 (1.1%) had a previous gastric cancer and 350 (9.1%) had 1 or more first- or second-degree relatives with gastric cancer. In multivariate analysis, male sex (odds ratio [OR], 2.82; 95% CI, 1.48-5.38), older age (OR, 2.07 per 10 years; 95% CI, 1.64-2.61), mutations in MLH1 (OR, 6.53; 95% CI, 1.50-28.42) or MSH2 (OR, 5.23 compared to mutations in MSH6, PMS2, or EPCAM; 95% CI, 1.21-22.71), and number of first-degree relatives with gastric cancer (OR, 2.52; 95% CI, 1.42-4.45), but not second-degree relatives (OR, 1.12; 95% CI, 0.40-3.18) were independently associated with gastric cancer among carriers of pathogenic mutations. CONCLUSIONS: In an analysis of data from almost 4000 carriers of Lynch syndrome-associated mutations, we found history of gastric cancer to be independently associated with male sex, older age, mutations in MLH1 or MSH2, and number of first-degree relatives with gastric cancer. These findings suggest that personalized, risk-stratified approaches to gastric cancer surveillance may be appropriate for individuals with Lynch syndrome-associated mutations.
BACKGROUND & AIMS:Lynch syndrome is the most common inherited cause of gastrointestinal cancer and increases risk for a variety of malignancies, including gastric cancer. We aimed to identify clinical factors associated with gastric cancer in carriers of germline variants causing Lynch syndrome. METHODS: We collected data from 52,758 consecutive individuals tested for genetic variants associated with Lynch syndrome from June 2006 through July 2013 at a commercial laboratory. We obtained clinical and demographic data, as well as information on personal and family histories of cancer (first- and second-degree relatives) from forms completed by ordering providers. We performed multivariate logistic regression to identify clinical factors associated with gastric cancer in carriers of mutations that cause Lynch syndrome (pathogenic mutations). RESULTS: After we excluded individuals with missing clinical data (n = 1664) or with multiple pathogenic mutations (n = 8), we analyzed data from 51,086 individuals. Of these, 3828 persons carried pathogenic mutations (1346 with mutations in MLH1, 1639 with mutations in MSH2, 670 with mutations in MSH6, 145 with mutations in PMS2, and 28 with mutations in EPCAM). Of the 3828 carriers of pathogenic mutations, 41 (1.1%) had a previous gastric cancer and 350 (9.1%) had 1 or more first- or second-degree relatives with gastric cancer. In multivariate analysis, male sex (odds ratio [OR], 2.82; 95% CI, 1.48-5.38), older age (OR, 2.07 per 10 years; 95% CI, 1.64-2.61), mutations in MLH1 (OR, 6.53; 95% CI, 1.50-28.42) or MSH2 (OR, 5.23 compared to mutations in MSH6, PMS2, or EPCAM; 95% CI, 1.21-22.71), and number of first-degree relatives with gastric cancer (OR, 2.52; 95% CI, 1.42-4.45), but not second-degree relatives (OR, 1.12; 95% CI, 0.40-3.18) were independently associated with gastric cancer among carriers of pathogenic mutations. CONCLUSIONS: In an analysis of data from almost 4000 carriers of Lynch syndrome-associated mutations, we found history of gastric cancer to be independently associated with male sex, older age, mutations in MLH1 or MSH2, and number of first-degree relatives with gastric cancer. These findings suggest that personalized, risk-stratified approaches to gastric cancer surveillance may be appropriate for individuals with Lynch syndrome-associated mutations.
Authors: Fay Kastrinos; Hajime Uno; Chinedu Ukaegbu; Carmelita Alvero; Ashley McFarland; Matthew B Yurgelun; Matthew H Kulke; Deborah Schrag; Jeffrey A Meyerhardt; Charles S Fuchs; Robert J Mayer; Kimmie Ng; Ewout W Steyerberg; Sapna Syngal Journal: J Clin Oncol Date: 2017-05-10 Impact factor: 44.544
Authors: Elena M Stoffel; Pamela B Mangu; Stephen B Gruber; Stanley R Hamilton; Matthew F Kalady; Michelle Wan Yee Lau; Karen H Lu; Nancy Roach; Paul J Limburg Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Lisette G Capelle; Nicole C T Van Grieken; Hester F Lingsma; Ewout W Steyerberg; Willem J Klokman; Marco J Bruno; Hans F A Vasen; Ernst J Kuipers Journal: Gastroenterology Date: 2009-11-10 Impact factor: 22.682
Authors: Eline C Soer; Laura W Leicher; Alexandra M J Langers; Paul C van de Meeberg; Egbert-Jan van der Wouden; Jan Jakob Koornstra; Marloes Bigirwamungu-Bargeman; Hans F A Vasen; Wouter H de Vos tot Nederveen Cappel Journal: Int J Colorectal Dis Date: 2016-02-04 Impact factor: 2.571
Authors: Pål Møller; Toni T Seppälä; Inge Bernstein; Elke Holinski-Feder; Paulo Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf H Sijmons; Jacqueline Jeffries; Hans F A Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul T Wijnen; Mark A Jenkins; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Mev Dominguez Valentin; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Maurizio Genuardi; Jukka-Pekka Mecklin; Gabriela Moeslein; Julian R Sampson; Gabriel Capella Journal: Gut Date: 2017-07-28 Impact factor: 23.059
Authors: Sanne W Ten Broeke; Heleen M van der Klift; Carli M J Tops; Stefan Aretz; Inge Bernstein; Daniel D Buchanan; Albert de la Chapelle; Gabriel Capella; Mark Clendenning; Christoph Engel; Steven Gallinger; Encarna Gomez Garcia; Jane C Figueiredo; Robert Haile; Heather L Hampel; John L Hopper; Nicoline Hoogerbrugge; Magnus von Knebel Doeberitz; Loic Le Marchand; Tom G W Letteboer; Mark A Jenkins; Annika Lindblom; Noralane M Lindor; Arjen R Mensenkamp; Pål Møller; Polly A Newcomb; Theo A M van Os; Rachel Pearlman; Marta Pineda; Nils Rahner; Egbert J W Redeker; Maran J W Olderode-Berends; Christophe Rosty; Hans K Schackert; Rodney Scott; Leigha Senter; Liesbeth Spruijt; Verena Steinke-Lange; Manon Suerink; Stephen Thibodeau; Yvonne J Vos; Anja Wagner; Ingrid Winship; Frederik J Hes; Hans F A Vasen; Juul T Wijnen; Maartje Nielsen; Aung Ko Win Journal: J Clin Oncol Date: 2018-08-30 Impact factor: 50.717
Authors: Jonathan W Wischhusen; Chinedu Ukaegbu; Tara G Dhingra; Hajime Uno; Fay Kastrinos; Sapna Syngal; Matthew B Yurgelun Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-15 Impact factor: 4.254
Authors: Shria Kumar; Christina M Dudzik; Mallory Reed; Jessica M Long; Kirk J Wangensteen; Bryson W Katona Journal: Cancer Prev Res (Phila) Date: 2020-08-28
Authors: Amanda H Ceravolo; Janie J Yang; Alicia Latham; Arnold J Markowitz; Jinru Shia; Joe Mermelstein; Delia Calo; Hans Gerdes; Emmy Ludwig; Mark A Schattner; Zsofia K Stadler; Elizabeth Kantor; Mengmeng Du; Robin B Mendelsohn Journal: Int J Colorectal Dis Date: 2021-10-26 Impact factor: 2.571
Authors: Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn Journal: Cancers (Basel) Date: 2021-01-22 Impact factor: 6.639